Theresa Ringenberg1, Heather Desanto2, Yekaterina Opsha3, Jennifer Costello4, Daryl Schiller5. 1. PGY-2 Pharmacy Resident. 2. Transplant Clinical Pharmacist. 3. Clinical Assistant Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, New Jersey; ; Cardiology Clinical Pharmacist. 4. Ambulatory Care Clinical Pharmacist. 5. Assistant Director of Clinical Pharmacy Services, Pharmacy Department, St. Barnabas Medical Center, Livingston, New Jersey. Corresponding author: Theresa Ringenberg, PharmD, 5754 Wickershire Lane, St. Louis, MO 63129; phone: 314-680-5593; e-mail: tmringenberg@gmail.com.
Abstract
BACKGROUND: It is unknown whether coagulation properties differ between renal transplant and nontransplant patients. OBJECTIVE: To assess whether renal transplant patients on intravenous (IV) heparin, titrated to therapeutic activated partial thromboplastin times (aPPT; 56-93 seconds), experienced a higher rate of bleeding compared to nontransplant patients. METHODS: Twenty-nine renal transplant and 29 nontransplant patients receiving IV heparin for a deep vein thrombosis, pulmonary embolism, atrial fibrillation, or acute coronary syndrome were randomly identified through a retrospective chart review. RESULTS: Renal transplant patients had higher bleeding rates on IV heparin therapy compared to nontransplant patients (31% vs 6.9%, respectively; P = .041). Renal transplant patients experienced a drop in hemoglobin of at least 1 g/dL or the need for a transfusion more often then nontransplant patients (69% vs 45%, respectively; P = .111), although the difference was not statistically significant. CONCLUSIONS: Further research is necessary to identify the factors contributing to increased rates of bleeding in renal transplant patients on IV heparin and to determine the ideal aPTT to appropriately balance anticoagulation in renal transplant patients.
BACKGROUND: It is unknown whether coagulation properties differ between renal transplant and nontransplant patients. OBJECTIVE: To assess whether renal transplantpatients on intravenous (IV) heparin, titrated to therapeutic activated partial thromboplastin times (aPPT; 56-93 seconds), experienced a higher rate of bleeding compared to nontransplant patients. METHODS: Twenty-nine renal transplant and 29 nontransplant patients receiving IV heparin for a deep vein thrombosis, pulmonary embolism, atrial fibrillation, or acute coronary syndrome were randomly identified through a retrospective chart review. RESULTS:Renal transplantpatients had higher bleeding rates on IV heparin therapy compared to nontransplant patients (31% vs 6.9%, respectively; P = .041). Renal transplantpatients experienced a drop in hemoglobin of at least 1 g/dL or the need for a transfusion more often then nontransplant patients (69% vs 45%, respectively; P = .111), although the difference was not statistically significant. CONCLUSIONS: Further research is necessary to identify the factors contributing to increased rates of bleeding in renal transplantpatients on IV heparin and to determine the ideal aPTT to appropriately balance anticoagulation in renal transplantpatients.
Authors: G S Friedman; H U Meier-Kriesche; B Kaplan; A S Mathis; L Bonomini; N Shah; P DeFranco; M Jacobs; S Mulgaonkar; S Geffner; N Lyman; C Paraan; C Walsh; W Belizaire; M Tshibaka Journal: Transplantation Date: 2001-09-27 Impact factor: 4.939
Authors: Seth R Bauer; Narith N Ou; Benjamin J Dreesman; Jeffrey J Armon; Jan A Anderson; Stephen S Cha; Lance J Oyen Journal: Mayo Clin Proc Date: 2009-12 Impact factor: 7.616
Authors: Paul E Morrissey; Pedro J Ramirez; Reginald Y Gohh; Angelito Y Yango; Anita Kestin; Peter N Madras; Anthony P Monaco Journal: Am J Transplant Date: 2002-10 Impact factor: 8.086